{
  "trial_id": "NCT03477240",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "approximately 1-2 weeks prior to her expected date of follow up",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "conversation and invited to participate in the study",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "verbal telephonic consent is obtained",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "interviewed by the clinical research nurse using the format of the prepared proforma (Form A)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "symptoms suggestive of disease recurrence as well as treatment induced toxicity",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "worrisome symptoms of disease or not and has symptoms of treatment toxicity or not for which she should visit the hospital",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "short written informed consent is taken",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "complete history and physical examination and any investigations he/she deems necessary",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "final impression of disease status and toxicity which are taken as the gold standard (Form B)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "information regarding the acceptability of nurse-led telephonic follow-up to the patient and the financial impact of physical follow- up will be collected using a structured format (Form C)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "patient is contactable by telephone",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Stage III disease treated with palliative intent with once monthly radiotherapy",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "Early stage cervical cancer patients who underwent Wertheims hysterectomy and who have completed adjuvant radiochemotherapy due to high-risk factors",
      "label": "triggers",
      "evidence": "none"
    }
  ],
  "notes": "The patient has myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive.",
  "_meta": {
    "topic_id": "38",
    "trial_id": "NCT03477240",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}